Security
Guardian Pharmacy Services, Inc. · GRDN
GRDNNYSECommon stockCurrentCIK 1802255Updated Oct 3, 2026
Name history
Guardian Pharmacy Services, Inc. · through Sep 28, 2026Guardian Pharmacy, LLC · through Jul 23, 2021
GRDN price & chart
Loading TradingView…
NYSE:GRDN on TradingView ↗About the company
Guardian Pharmacy Services is one of the nation’s leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities (“LTCFs”) to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of 61 licensed pharmacies, of which 54 are full-service, Guardian is dedicated to providing exceptional service to approximately 207,000 residents (as of March 31, 2026).
In the news
No coverage from other publishers is available.
Recent filings
4 filing
4 filing
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
S-8 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 412,658,000Source | 320,810,000Source |
| Property, Plant and Equipment, NetUSD | 55,522,000Source | 49,883,000Source |
| GoodwillUSD | 79,743,000Source | 69,296,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 18,475,000Source | 14,912,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 65,619,000Source | 4,660,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 101,614,000Source | 97,153,000Source |
| Inventory, NetUSD | 43,359,000Source | 40,550,000Source |
| Assets, CurrentUSD | 221,634,000Source | 151,985,000Source |
| Operating Lease, Right-of-Use AssetUSD | 34,649,000Source | 29,079,000Source |
| Other Assets, NoncurrentUSD | 436,000Source | 383,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 194,734,000Source | 170,834,000Source |
| Stockholders’ equity: | ||
| Additional Paid in CapitalUSD | 139,353,000Source | 125,484,000Source |
| Retained Earnings (Accumulated Deficit)USD | 66,343,000Source | 17,124,000Source |
| Liabilities and EquityUSD | 412,658,000Source | 320,810,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 160,703,000Source | 144,121,000Source |
| Operating Lease, Liability, CurrentUSD | 7,150,000Source | 6,836,000Source |
| Accounts Payable, CurrentUSD | 116,206,000Source | 102,420,000Source |
| Operating Lease, Liability, NoncurrentUSD | 29,992,000Source | 23,297,000Source |
| Other Liabilities, NoncurrentUSD | 4,039,000Source | 3,416,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 12,165,000Source | 7,305,000Source |
| Additional Financial Items | ||
| Long-term DebtUSD | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 48,958,000Source | -71,033,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 22,335,000Source | 19,772,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 13,850,000Source | 131,490,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts ReceivableUSD | 8,553,000Source | 25,485,000Source |
| Increase (Decrease) in InventoriesUSD | 877,000Source | 1,151,000Source |
| Increase (Decrease) in Accounts PayableUSD | 16,398,000Source | 13,230,000Source |
| Deferred Income Tax Expense (Benefit)USD | 3,074,000Source | 701,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 100,255,000Source | 57,960,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -32,225,000Source | -30,407,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -7,071,000Source | -23,645,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 60,959,000Source | 3,908,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 65,619,000Source | 4,660,000Source |
| Supplemental disclosure of cash flow information: | ||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 650,000Source | 3,121,000Source |
| Income Taxes Paid, NetUSD | 21,541,000Source | 0Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 13,850,000Source | 131,490,000Source |
| GoodwillUSD | 79,743,000Source | 69,296,000Source |
| Goodwill, Impairment LossUSD | 0Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 48,958,000Source | -71,033,000Source |
| Income Tax Expense (Benefit)USD | 24,465,000Source | 4,556,000Source |
| InterestExpenseNonoperatingUSD | 665,000Source | 3,278,000Source |
| Net Income (Loss) Attributable to ParentUSD | 49,219,000Source | -110,047,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -261,000Source | 16,254,000Source |
| Nonoperating Income (Expense)USD | 722,000Source | -3,557,000Source |
| Other Nonoperating Income (Expense)USD | 1,387,000Source | -279,000Source |
| Proceeds from Issuance of Common StockUSD | 29,039,000Source | 119,784,000Source |
| Proceeds from Noncontrolling InterestsUSD | 1,970,000Source | 2,758,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 1,448,685,000Source | 1,228,409,000Source |
| Cost of RevenueUSD | 1,155,967,000Source | 984,038,000Source |
| Selling, General and Administrative ExpenseUSD | 220,017,000Source | 307,291,000Source |
| Operating Income (Loss)USD | 72,701,000Source | -62,920,000Source |
| Other Nonoperating Income (Expense)USD | 1,387,000Source | -279,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 73,423,000Source | -66,477,000Source |
| Income Tax Expense (Benefit)USD | 24,465,000Source | 4,556,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -261,000Source | 16,254,000Source |
| Net Income (Loss) Attributable to ParentUSD | 49,219,000Source | -110,047,000Source |
| Interest Expense (non-operating)USD | 665,000Source | 3,278,000Source |
| Additional Financial Items | ||
| Current Income Tax Expense (Benefit)USD | 21,391,000Source | 3,855,000Source |
| Goodwill, Impairment LossUSD | 0Source | — |
| Gross ProfitUSD | 292,718,000Source | 244,371,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 48,958,000Source | -71,033,000Source |
| Marketing and Advertising ExpenseUSD | 3,895,000Source | 3,502,000Source |
| Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, RedeemableUSD | — | -96,000Source |
| Nonoperating Income (Expense)USD | 722,000Source | -3,557,000Source |
Filing attachments
d160709dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d160709dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 - Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, announced today its financial results for the second quarter ended June 30, 2026. The Company also raised its full-year guidance. Second Quarter Financial Results Revenue of $351.…
Read attachment ↗d97841dex991.htm · 8-K · 2026-06-22
EX-99.1 2 d97841dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services, Inc. Announces Leadership Transitions Executive Vice President Kendall Forbes to Retire on July 1, 2026 Guardian Names David Morris as Chief Operating Officer and Will Mudd as Chief Financial Officer ATLANTA, GA - Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that Kendall Forbes, who has served as Executive Vice President of Sales & Operations since 2004, has decided to retire, effective …
Read attachment ↗d132626dex991.htm · 8-K · 2026-05-06
EX-99.1 2 d132626dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports First Quarter 2026 Financial Results; Updates Full-Year Guidance ATLANTA, May 6, 2026 - Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, announced today its financial results for the first quarter ended March 31, 2026. The Company also updated its full-year guidance. First Quarter Financial Results Revenue of $336.6 m…
Read attachment ↗